We employ a totality approach in our accelerated development of insulin biosimilars, and this is our cornerstone and fundamental principle to achieve our mission. We are focused on our core strengths such as development, scale-up, technology transfer and manufacturing, while trusting our partners for their commercialization capabilities and the simplification of supply chain for diabetes patients.